A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...

Based on these data, we believe that further development of subcutaneous sabirnetug as ... frequently reported adverse events included injection site reactions (62.5%), all of which were mild ...

Helicore Biopharma has dosed the first subject in the randomised first-in-human Phase I trial of HCR-188 to treat obesity.

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Weekly subcutaneous administration of sabirnetug ... The most frequently reported adverse events included injection site reactions (62.5%), all of which were mild (Grade 1) in severity and resolved.

A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a c ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...